Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.
Launched by ABIONIC SA · Mar 16, 2018
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adult patients (age ≥ 18 years)
- • 2. Requiring ICU management
- • 3. At high risk of sepsis (septic patients are excluded)
- • 4. Expected ICU stay for more than 4 days
- • 5. Have provided written informed consent or consent is given by the patient's legally designated representative.
- Exclusion Criteria:
- • 1. Patient expected to die within 48 hours of admission to ICU
- • 2. Patient suffering from or known acute or chronic pancreatitis, pancreatic cancer or admitted after pancreatectomy, but if a patient develops any pancreatic disease during the IUC stay he/she will remain in the study.
About Abionic Sa
Abionic SA is an innovative biotechnology company specializing in the development of rapid diagnostic tests that leverage advanced nanotechnology to improve patient care. Headquartered in Switzerland, Abionic focuses on creating efficient and cost-effective solutions for the early detection of critical health conditions, enabling timely medical interventions. With a commitment to enhancing diagnostic accuracy and accessibility, the company aims to transform the landscape of point-of-care testing, ultimately contributing to better health outcomes worldwide. Through rigorous clinical trials and collaborations, Abionic is dedicated to advancing its pioneering technologies in the healthcare sector.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Le Mans, , France
Limoges, , France
Pierre Bénite, , France
Tours, , France
Perugia, , Italy
Ravenna, , Italy
Rimini, , Italy
Torino, , Italy
Bern, , Switzerland
Geneva, , Switzerland
Lausanne, , Switzerland
Guildford, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials